Inactive Instrument

Phytopharm plc Stock London S.E.

Equities

GB0006869720

Biotechnology & Medical Research

End-of-day quote London S.E.
- GBX - Intraday chart for Phytopharm plc
Sales 2024 * 5.2M 6.49M Sales 2025 * - Capitalization 4.17M 5.21M
Net income 2024 * -2M -2.5M Net income 2025 * - EV / Sales 2024 * 0.53 x
Net cash position 2024 * 1.4M 1.75M Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.57 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 52.5%
More Fundamentals * Assessed data

Latest transcript on Phytopharm plc

Managers TitleAgeSince
Chief Executive Officer 63 17-02-05
Director of Finance/CFO 47 19-05-30
Chairman 59 13-10-13
Members of the board TitleAgeSince
Chairman 59 13-10-13
Director/Board Member 48 16-09-15
Director/Board Member 60 23-10-04
More insiders
IXICO plc is a United Kingdom-based company that provides specialist data analytics services to the global biopharmaceutical industry. The services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. The outputs from the data analysis are used to enhance patient selection, monitor drug safety, and assess clinical efficacy of the drug under development. It offers a range of services, such as drug development analytics, imaging operations, post-marketing, and post-marketing. It offers end to end services, including trial design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. It offers a range of clinical trial imaging analysis tools, including radiological reads, structural and advanced magnetic resonance imaging (MRI). Its specialist data analytics services identify and measure biomarkers from brain scans and wearable biosensors.
More about the company